Lauren A Byers
Overview
Explore the profile of Lauren A Byers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
7178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shields M, Chiang A, Byers L
Cancer
. 2025 Mar;
131(6):e35770.
PMID: 40040254
Lung cancer remains the leading cause of cancer-related mortality in both men and women. Small cell lung cancer (SCLC) is notorious for its early metastatic spread, aggressive biology, and high...
2.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
3.
Meric-Bernstam F, Yuca E, Evans K, Zhao M, Maejima T, Karibe T, et al.
Clin Cancer Res
. 2024 Nov;
31(3):573-587.
PMID: 39585341
Purpose: Datopotamab deruxtecan (Dato-DXd) is a humanized anti-trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to a potent topoisomerase I inhibitor payload (DXd). Dato-DXd has already shown antitumor activity in breast...
4.
Karim N, Miao J, Reckamp K, Gay C, Byers L, Zhao Y, et al.
J Thorac Oncol
. 2024 Nov;
20(3):383-394.
PMID: 39505259
Objective: To evaluate whether the addition of a poly (adenosine diphosphate-ribose) polymerase inhibitor talazoparib to maintenance immune checkpoint inhibitor atezolizumab after frontline chemoimmunotherapy improved outcomes in patients with Schlafen 11...
5.
Murray C, Kornepati A, Ontiveros C, Liao Y, de la Pena Avalos B, Rogers C, et al.
Mol Cancer
. 2024 Oct;
23(1):242.
PMID: 39478560
Background: Aside from the canonical role of PDL1 as a tumour surface-expressed immune checkpoint molecule, tumour-intrinsic PDL1 signals regulate non-canonical immunopathological pathways mediating treatment resistance whose significance, mechanisms, and therapeutic...
6.
Zhou N, Leung C, William Jr W, Weissferdt A, Pataer A, Godoy M, et al.
J Immunother Cancer
. 2024 Oct;
12(10.
PMID: 39448200
Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the...
7.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
8.
Morris B, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, et al.
bioRxiv
. 2024 Aug;
PMID: 39211077
Introduction: A hallmark of small cell lung cancer (SCLC) is its recalcitrance to therapy. While most SCLCs respond to frontline therapy, resistance inevitably develops. Identifying phenotypes potentiating chemoresistance and immune...
9.
Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, et al.
Res Sq
. 2024 Jun;
PMID: 38826463
Traditional feature dimension reduction methods have been widely used to uncover biological patterns or structures within individual spatial transcriptomics data. However, these methods are designed to yield feature representations that...
10.
Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, OBrien C, et al.
Mol Cancer
. 2024 May;
23(1):115.
PMID: 38811992
Background: We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP,...